在肌缩侧面硬化症中准代谢功能障碍:GLP-1受体激活剂的治疗潜力
Mohamed Mohsen Helal1, Nereen A Almosilhy2, Dina Essam Abo-Elnour1,3
1Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Amyotrophic lateral sclerosis & frontotemporal degeneration
|February 12, 2026
概括
类似葡萄糖类-1受体激动剂 (GLP-1RAs) 显示出因代谢和神经保护作用而具有潜在的amyotrophic lateral sclerosis (ALS) 治疗潜力. 然而,目前的临床数据有限,并引发了安全问题,表明ALS患者的疗效不确定.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 代谢功能障碍 代谢功能障碍
- 药理疗法 药理疗法 药理疗法
背景情况:
- 肌缩性侧面硬化症 (ALS) 涉及运动神经元的损失和显著的代谢问题,如高代谢和胰岛素抵抗.
- 在ALS中的代谢异常促使对抗糖尿病药物的研究,特别是类似葡萄糖-1受体激动剂 (GLP-1RAs).
- GLP-1RAs具有超出代谢控制的神经保护性质,包括抗炎和细胞存活效应.
研究的目的:
- 审查ALS中的代谢障碍.
- 评估使用基于GLP-1的治疗方法在ALS的理由和证据.
- 评估ALS治疗GLP-1RAs的临床前和临床数据.
主要方法:
- 现有文献的叙述性审查.
- 在ALS模型中对临床前研究的分析.
- 对ALS中的GLP-1RAs新出现的临床试验数据的评估.
主要成果:
- 临床前研究表明,在ALS模型中GLP-1信号的神经保护作用是混合的,这取决于特定的药物和研究设计.
- 有限的临床证据不支持GLP-1RAs在ALS中的治疗益处.
- 在ALS中临床使用GLP-1RA与安全问题有关,包括减肥和改变葡萄糖调节,这可能会使预后恶化.
结论:
- 虽然GLP-1RA对神经退行有理论上的好处,但它们在ALS中的作用是不确定的,可能是有害的.
- 目前的数据表明,GLP-1RA可能对ALS有害,因为它对体重和新陈代谢产生不良影响.
- 此外,需要进行精心设计的,针对ALS的临床试验,以便在考虑GLP-1RA用于ALS治疗之前确定安全性和有效性.
相关概念视频
Adrenergic Agonists: Therapeutic Uses
2.0K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K
Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Adrenergic Agonists: Therapeutic Classification
1.7K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.7K
Drug-Receptor Interaction: Agonist
4.2K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.2K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.8K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.8K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.0K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.0K


